scispace - formally typeset
M

Martin Grond

Researcher at University of Marburg

Publications -  109
Citations -  7159

Martin Grond is an academic researcher from University of Marburg. The author has contributed to research in topics: Stroke & Thrombolysis. The author has an hindex of 34, co-authored 95 publications receiving 6452 citations. Previous affiliations of Martin Grond include Max Planck Society & Darmstadt University of Applied Sciences.

Papers
More filters
Journal ArticleDOI

Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study

Nils Wahlgren, +14 more
- 27 Jan 2007 - 
TL;DR: These data confirm that intravenous alteplase is safe and effective in routine clinical use when used within 3 h of stroke onset, even by centres with little previous experience of thrombolytic therapy for acute stroke.
Journal ArticleDOI

Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source

Hans-Christoph Diener, +24 more
- 15 May 2019 - 
TL;DR: In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in preventing recurrent stroke, but there were more clinically relevant nonmajor bleeding events in the dabig atran group.
Journal ArticleDOI

Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST)

Nils Wahlgren, +18 more
- 01 Dec 2008 - 
TL;DR: The unadjusted results demonstrated that intravenous alteplase is well tolerated and that the effects were comparable with those seen in randomized, controlled trials (RCT) when used in routine clinical practice within 3 hours of ischemic stroke onset.
Journal ArticleDOI

Implementation and outcome of thrombolysis with alteplase 3–4·5 h after an acute stroke: an updated analysis from SITS-ISTR

Niaz Ahmed, +9 more
- 01 Sep 2010 - 
TL;DR: The implementation of the wider time window for intravenous alteplase treatment within 3-4.5 h after stroke has been implemented rapidly, with a simultaneous increase in the number of patients treated within 3 h; admission-to-treatment time has not increased.
Journal ArticleDOI

The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Menno V. Huisman, +1027 more
- 21 Feb 2017 - 
TL;DR: GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombinotic t...